American Society of Clinical Oncology (ASCO)

Tucatinib Plus Trastuzumab Plus Capecitabine Is Efficacious After Trastuzumab Deruxtecan Exposure in HER2-Positive MBC

Interim results from the Asia cohort of the HER2 REAL study found heterogeneous treatment patterns among patients with HER2-positive unresectable locally advanced or metastatic breast cancer progressing on HER2-directed therapies. Read More ›

PERMEATE: Updated Results of Pyrotinib Plus Capecitabine in Patients With HER2-Positive MBC and Brain Metastases

Results of a large multicenter retrospective study confirmed that tucatinib in combination with trastuzumab and capecitabine was efficacious in patients with HER2-positive metastatic breast cancer with previous exposure to trastuzumab deruxtecan. Read More ›

HER2CLIMB-05: Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for HER2-Positive LA/MBC

Updated results of the phase 2 PERMEATE trial confirmed that pyrotinib plus capecitabine provided long-term survival benefit in patients with HER2-positive metastatic breast cancer and brain metastases. Read More ›

PRECIOUS: Pertuzumab Re-treatment Improved OS in HER2-Positive LA/MBC in a Phase 3 Trial, but Did Treatment Imbalances Impact the Outcomes?

The phase 3 HER2CLIMB-05 trial is evaluating tucatinib plus trastuzumab and pertuzumab as maintenance therapy in patients with HER2-positive locally advanced or metastatic breast cancer. Read More ›

Updated results of the phase 3 randomized PRECIOUS trial demonstrated that dual HER2 blockade with pertuzumab re-treatment in combination with trastuzumab plus chemotherapy led to significant overall survival improvement compared with trastuzumab plus chemotherapy in patients previously treated with pertuzumab-containing regimens for HER2-positive locally advanced/metastatic breast cancer, but potential imbalances in chemotherapy during and after the study treatment period may have impacted the results. Read More ›

TROPiCS-02 Primary Results: Sacituzumab Govitecan versus Treatment of Physician’s Choice in Patients with Advanced Breast Cancer

The TROPiCS-02 study aims to confirm optimal treatment choice in patients with hormone receptor–positive/HER2-negative metastatic breast cancer whose disease progresses after having received endocrine therapy (ET) plus cyclin-dependent kinase (CDK)4/6 inhibitor. Read More ›

DESTINY-Breast04 Compared T-DXd with TPC in Patients with HER2-Low Breast Cancer

DESTINY-Breast04 is the first trial comparing outcomes with trastuzumab deruxtecan (T-DXd) versus treatment of physician’s choice (TPC) in patients with HER2-low metastatic breast cancer treated with 1 or 2 prior lines of chemotherapy. Read More ›

Ribociclib Efficacious in Patients with Unresectable or HR-Positive/HER2-Negative Metastatic Breast Cancer Receiving Fulvestrant or Exemestane After Not Responding to Prior Treatments

Patients with hormone receptor (HR)-positive/HER2-negative metastatic breast cancer who had previously advanced on any cyclin-dependent kinase (CDK)4/6 inhibitor plus any endocrine therapy (ET) showed a substantial progression-free survival (PFS) advantage in the ribociclib-treated cohort. Read More ›

Event-Free Survival by Residual Cancer Burden After Neoadjuvant Chemotherapy + Pembrolizumab for Early TNBC: KEYNOTE-522 Data

Pembrolizumab plus chemotherapy increased event-free survival compared with chemotherapy alone, highlighting the relevance of neoadjuvant pembrolizumab therapy for improving survival in patients with early triple-negative breast cancer. Read More ›

Final Results from the Phase 3 ASCENT Study: Sacituzumab Govitecan versus TPC in Patients with Previously Treated, Metastatic TNBC